Latest News
Cannabis Derived CBD Can Inhibit Expansion of Human Fat Cells by 60%, According to Can-Fite
Tuesday 21 September 2021

Israel-based biotechnology company Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) has released new pre-clinical data demonstrating that cannabis derived CBD enriched fractions, supplied by Univo Pharmaceuticals, inhibit the expansion of human fat cells (pre-adipocytes) by 60%, a result that points towards the potential anti-obesity effect of this agent, the company said.

Although it is already documented that cannabis derived compounds possess anti-obesity effect, the novel data presented by the company demonstrates the anti-obesity effect at low nano-molar concentrations.

Low CBD concentrations are known to be safe and well accepted in humans, the company said.

Can-Fite experience in this field is based on the development of its NASH drug Namodenoson which recently completed enrollment in its Phase II study.

The end points of this study include serum ALT levels, percentage change in liver fat, as measured by PDFF (proton density fat fraction), weight loss and additional serum parameters. Data are expected before the end of this quarter.

The global obesity treatment market is lucrative due to the awareness of a link between obesity and chronic diseases such as diabetes and NASH. According to Market Research Future, the global obesity treatment market is expected to exceed USD 12bn by 2023.

The company expects to release data from its Phase II NAFLD/NASH study of Namodenoson during 1Q20.

Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor. Namodenoson is being evaluated as a second line treatment for hepatocellular carcinoma, with a recently completed Phase II trial and planned Phase III trial in this indication.

The drug is currently in an ongoing Phase II trial as a treatment for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis. A3AR is highly expressed in diseased cells whereas low expression is found in normal cells. This differential effect accounts for the excellent safety profile of the drug.
Date Published: 21/09/2021